Articles tagged with Sars Cov
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
A synthetic glycosystem mimics natural sugars on human cells, binding to virus's spike protein and preventing infection. The molecule was found to be effective at low doses and worked against multiple SARS-CoV-2 strains.
Researchers discovered a novel coronavirus in bats in Brazil with similarities to the Middle East respiratory syndrome virus. The five bats belonged to two species and showed significant genetic diversity, prompting experiments to determine whether it can infect humans.
Researchers developed a new 'proactive vaccinology' approach to build vaccines before disease-causing pathogens emerge. The Quartet Nanocage vaccine trains the immune system to target specific regions of eight coronaviruses, providing broad protection against known and unknown strains.
A new study published in PLOS ONE found that COVID-19 infections cause significant physiological differences between males and females. Males experience larger increases in skin temperature, breathing rate, and heart rate during infections, while also maintaining higher levels during recovery.
Researchers have uncovered a novel mechanism of cell death regulation, shedding light on its significance during conditions such as SARS-CoV infection and skin injury. The study reveals that the cleavage of cFLIP restrains cell death during viral infection and tissue injury, favoring tissue repair.
A University of Ottawa-led team identified a new entry route for SARS-CoV-2 using metalloproteinases, which may lead to more widespread cell infection and severe illness. The study suggests that variants like the Delta strain may prefer this entry method, while others like Omicron do not.
Researchers have identified a tailor-made pocket feature in the spike glycoproteins of deadly coronaviruses, including SARS-CoV-2, MERS, and Omicron. This finding could lead to the development of a pan-coronavirus treatment that exploits this pocket feature to stop virus infectivity.
CoVaRR-Net is investing $6.9 million in 15 research projects focused on understanding Omicron subvariants and finding solutions to curb their spread. The studies will explore various aspects of variants, including viral transmission between animals and people, new variant mutations, and the impact of social factors on Indigenous Peoples.
Researchers discovered a potent universal coronavirus therapy that targets the S2 stalk region of the viral spike protein, highly conserved among beta-coronaviruses. The monoclonal antibody protected against infections when given as an intraperitoneal injection or nasal dose in animal experiments.
Researchers have discovered llama-derived immune particles that provide strong protection against a vast array of SARS-like viruses, including COVID-19. These 'super-immunity' molecules, known as nanobodies, could be used to develop a fast-acting, inhalable antiviral treatment or spray.
Researchers from Osaka University have developed an engineered ACE2 decoy that effectively reduces the rate and severity of infection with the Omicron variant under laboratory conditions. The decoy mimics the SARS-CoV-2 receptor, preventing the virus from binding to cells and entering them.
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
The NIAID plans to identify prototype pathogens with potential to cause significant human disease, building a framework for rapid research and product development. The institute also focuses on priority pathogens known to cause significant human illness or death.
A new study reveals that SARS-CoV-2 limits viral particle release and instead spreads through cell-to-cell transmission, enabling efficient infection without the need for antibodies. This stealthy transmission method makes it challenging for the host immune system to target and neutralize the virus.
Scientists have developed a fusion protein that successfully blocks replication of SARS-CoV-2 and related viruses in cell culture tests. The protein combines ACE2 with human antibody fragments, providing reliable protection against future mutations.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
Researchers found that SARS-CoV-2 prefers to replicate at temperatures typical of the upper airways, whereas replication of SARS-CoV was not impacted by temperature. This understanding provides new insights into virus-host interactions and potential targets for intervention strategies.
Researchers found that SARS-CoV-2's spike protein moves on a different time scale than SARS-CoV-1, giving it more stability and increasing its ability to infect cells. This discovery could lead to the development of therapeutics that alter the protein's dynamics and make it less transmissible.
Researchers discover that SARS-CoV-2 and SARS-CoV-1 share similarities due to a recombination event involving the ACE2 receptor. The study provides evolutionary context for these viruses' behavior, enabling researchers to identify high-risk viruses and estimate their potential for human spillover.
Researchers from UTEP and Howard University discovered valuable data comparing fundamental mechanisms of SARS-CoV and SARS-CoV-2 to better understand how these viruses attack the human body. They found that mutations make SARS-CoV-2 significantly more contagious and prone to cause serious infections.
Researchers are investigating the antiviral properties of Respiratory Detox Shot (RDS), a traditional Chinese medicine that blocks SARS-CoV and CoV-2 entry into human cells. Wu's lab aims to quantify RDS cytotoxicity in human cells.
An international team of researchers analyzed medical records and identified commonly hijacked cellular pathways in three lethal coronaviruses. The study revealed treatment regimens for current and potential future viral pandemics, providing real-world implications for COVID-19 treatment.
Researchers found that serum antibodies from recovered SARS patients effectively neutralized SARS-CoV-2 in vitro. The study also discovered that mice and rabbits immunized with a specific RBD elicited stronger antibody responses against SARS-CoV-2.
A study found that SARS-CoV-2's ORF3b is a potent interferon antagonist, impairing the immune system in COVID-19 patients. This may explain the disease's poor induction of type I interferon responses.
Researchers found that patients infected with SARS-CoV-2 produce antibodies that bind to other coronaviruses, but these antibodies are not cross-protective. The study suggests that more research is needed to identify critical virus parts for a cross-protective immune response.
A promising COVID-19 drug, valinomycin, has been produced in a cell-free system, achieving higher concentrations than previously achieved in cells. This approach enables faster optimization and increased yields, which could be crucial in the fight against the pandemic.
The study found SARS-CoV-2 stable in aerosols for up to three hours and on copper for up to four hours, while also detectable for 24 hours on cardboard and two to three days on plastic and stainless steel. This stability suggests people may acquire the virus through air and after touching contaminated objects.
Researchers have developed compounds that can block the replication of similar coronaviruses and other disease-causing viruses. The compounds target a shared protein-cutting enzyme essential for viral replication, showing strong activity against some viruses like MERS-CoV.
Researchers found similarities between the novel Wuhan coronavirus's receptors and those of SARS-CoV, a key finding in understanding its ability to infect humans. The study suggests that mutations in the virus could enhance its binding to human ACE2, leading to increased transmission.
New research from the National Institute of Allergy and Infectious Diseases (NIAID) shows that MERS-CoV can adapt to infect cells of a new species, similar to SARS-CoV. This finding suggests that other coronaviruses might be able to do the same, potentially leading to new human infections.
A new coronavirus identified in bats is linked to the devastating death of nearly 25,000 piglets in China. The virus, named SADS-CoV, does not infect humans and was contained through swift action by farmers.
A new study develops a live attenuated SARS-CoV vaccine that maintains genetic stability through targeted modifications of the E protein gene. Vaccinated mice show full protection against challenge with virulent SARS-CoV, demonstrating potential as an efficient and safe vaccine.
A study compared the population dynamics of MERS-CoV and SARS-CoV infections, finding that MERS-CoV predominantly affects males with multiple chronic conditions. This research highlights key differences between the two diseases, including mortality rates and transmission patterns.
Scientists identified a compound that effectively inhibits an enzyme crucial to Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) viruses. The compound has a different mode of action for each virus due to slight differences in the enzyme.
A new experimental vaccine developed by Novavax has been shown to induce a neutralizing antibody response in mice, blocking infection with the MERS-CoV virus. The vaccine uses recombinant nanoparticle technology and is based on the major surface spike protein of SARS-CoV and MERS-CoV.
A team of scientists isolated a live virus from horseshoe bats in China, confirming them as the origin of the SARS-CoV. The discovery will help governments design effective prevention strategies for similar epidemics.
Researchers have generated a synthetic SARS-like bat coronavirus that is infectious in cultured cells and mice, identifying pathways by which a bat coronavirus may have adapted to infect humans. The findings provide a model approach for rapid identification, analysis, and public health responses to future natural or intentional virus e...
New analysis suggests SARS originated in bats, not palm civet cats as previously thought. The study reveals humans were the source of the virus found in those animals, contrary to earlier findings.
Researchers used glycan microarrays to explore novel immunologic targets for SARS-CoV. The study found undesired autoantibody reactivity against human serum glycoprotein ASOR, prompting concerns over the safety of whole-viral SARS vaccines.
A recent study examines seroprevalence of non-pneumonic SARS-CoV infections in general population and healthcare workers. The findings suggest that non-pneumonic infections are more common than SARS-CoV pneumonia, shedding light on possible explanations for cases with no obvious contact to other patients.
A novel coronavirus has been confirmed as the primary causal agent of SARS, according to a study. The virus was found to infect the lower respiratory tract, leading to severe lung damage and disease symptoms. The discovery was made through laboratory studies of patients and experimental infections in macaques.
Researchers have identified two distinct genotypes of the SARS virus, linked to geographic clusters of infections. The study provides valuable insights into the genetic makeup of the virus, which could inform public health strategies and vaccine development.